肿瘤坏死因子-α拮抗剂治疗静脉注射免疫球蛋白无反应型川崎病的研究进展  

Progress of Tumor Necrosis Factor-αAntagonists in the Treatment of Intravenous Immunoglobulin Resistant Kawasaki Disease

作　　者：卜晓怡 易岂建[1] Bu Xiaoyi;Yi Qijian(Children’s Hospital of Chongqing Medical University,National Clinical Research Center for Child Health and Disorders,Education Key Laboratory of Research on Child Development and Disease,National Clinical Key Cardiovascular Specialty,Key Laboratory of Children’s Important Organ Development and Diseases of Chongqing Municipal Health Commission,Chongqing 400014,China)

机构地区：[1]重庆医科大学附属儿童医院,国家儿童健康与疾病临床医学研究中心,儿童发育疾病研究教育部重点实验室,国家临床心血管内科重点专科,重庆市卫生健康委儿童重要器官发育与疾病重点实验室,重庆400014

出　　处：《儿科药学杂志》2024年第10期57-60,共4页Journal of Pediatric Pharmacy

摘　　要：川崎病(Kawasaki disease,KD),也称为皮肤黏膜淋巴结综合征(mucocutaneous,limphonode syndrome,MCLS),是一种自限性系统性免疫性血管炎。该疾病导致的冠状动脉病变(coronary artery lesions,CALs)包括冠状动脉扩张(coronary artery dilation,CAD)。

关 键 词：冠状动脉扩张 皮肤黏膜淋巴结综合征 川崎病 静脉注射免疫球蛋白 免疫性血管炎 artery 冠状动脉病变 lesions 

分 类 号：R725.4[医药卫生—儿科]